Piper Sandler Resumes Supernus Coverage With Overweight Rating
Photo: TokenPost
Piper Sandler resumed coverage of Supernus Pharmaceuticals (SUPN) on Wednesday, Nov. 4, with an Overweight rating and a $47 price target, tying its view to the company’s announced merger with Indivior. The firm said combining the businesses would expand the merged company’s capacity for business development and acquisitions compared with what Supernus and Indivior could pursue separately. Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
